Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2017 | Pages:
100 | Publisher: Grand View Research
Industry: Biotechnology | Report Format: Electronic (PDF)
The global human embryonic stem cells (hESCs) market is anticipated to reach USD 1.06 billion by 2025, according to a new report by Grand View Research, Inc. Application of hESCs as a promising donor source for cellular transplantation therapies is anticipated to bolster progress through to 2025. hESCs technology tends to be useful for tissue engineering in humans due to high histocompatibility between host and graft. Maintenance of developmental potential for contribution of derivatives of all three germ layers is an important feature of these cells. This ability remains consistent even after clonal derivation or prolonged undifferentiated proliferation, thus pronouncing its accelerated uptake. In addition, these are capable in expressing high level of alkaline phosphatase, key transcription factors, and telomerase. These factors are found to be of great importance in the maintenance of the inner cellular mass pluripotency. Furthermore, hESCs can be easily differentiated into defined neurons, neural lineages, oligodendrocytes, and astrocytes. Aforementioned characteristic makes it useful in studying the sequence of events that take place during early neurodevelopment. However, use of stem cells derived from viable embryos is fraught with ethical issues, prompting scientists to explore other methods to generate ESCs. The other methods include derivation of embryonic germ cells, stem cells from dead embryos, and other techniques. Further Key Findings from the Study Suggest: hESC derivation provides a unique opportunity for early human development studies It is believed to hold a substantial potential for regenerative medicine and biopharma Differentiated derivatives of these cells are applicable for screening assays in development of novel pharmaceutical moieties Screening for mutagenic as well as toxic compounds can also be carried out using such derivatives Presence of lack of suitable donor organs and tissues for regenerative medicine is expected to increase the demand thus influencing growth Stem cell research is anticipated to exhibit fastest growth amongst the other applications However, presence of controversies pertaining to their use as a consequence of ethical considerations is responsible for steady growth Europe accounts for considerable share of the market, following North America As per a recent survey carried out by Swiss government, citizens there are more willing to accept embryonic stem cell research than politicians Asia Pacific is anticipated to drive market with fastest YoY growth Rising awareness amongst the population and physicians with respect to associated therapies is anticipated to propel progress Key players contributing in this market are CellGenix GmbH, International Stem Cell Corporation, Thermo Fisher Scientific, Inc.; Kite Pharma, PromoCell GmbH, and Lonza Presence of clinical trial pipeline for embryonic stem cell derived therapy for targeting different diseases is expected to fuel growth. The diseases targeted include macular degeneration, Parkinson's disease, type I diabetes mellitus, and spinal cord injury.
Table of Contents
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
Chapter 2 Executive Summary
Chapter 3 Human Embryonic Stem Cells Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market Driver Analysis
3.1.1.1 Technological advancement involving stem cells therapy
3.1.1.2 Rising demand for regenerative medicines
3.1.1.3 R&D in toxicology testing
3.1.1.4 Technological advanvcements for the production of embryonic stem cells through alternative methods
3.1.1.5 Increasing prevalence of genetic disorders
3.1.2 Market Restraint Analysis
3.1.2.1 Ethical concern related to stem cell research
3.2 Penetration & Growth Prospect Mapping for Application, 2015
3.3 Human embryonic stem cells -Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter's
Chapter 4 Human Embryonic Stem Cells Market: Application Estimates & Trend Analysis
4.1 Global Human Embryonic Stem Cells Market: Application Movement Analysis
4.2 Regenerative Medicine
4.2.1 Global regenerative medicine market, 2014 - 2025 (USD Million)
4.3 Stem Cell Biology Research
4.3.1 Global stem cell biology research market, 2014 - 2025 (USD Million)
4.4 Tissue Engineering
4.4.1 Global tissue engineering market, 2014 - 2025 (USD Million)
4.5 Toxicology Testing
4.5.1 Global toxicology testing market, 2014 - 2025 (USD Million)
Chapter 5 Human Embryonic Stem Cells Market: Regional Estimates & Trend Analysis, by Application
5.1 Human Embryonic Stem Cells Market Share By Region, 2015 & 2025
5.2 North America
5.2.1 North America human embryonic stem cells market, 2014 - 2025 (USD Million)
5.2.2 U.S.
5.2.2.1 U.S human embryonic stem cells market, 2014 - 2025 (USD Million)
5.2.3 Canada
5.2.3.1 Canada human embryonic stem cells market, 2014 - 2025 (USD Million)
5.3 Europe
5.3.1 Europe human embryonic stem cells market, 2014 - 2025 (USD Million)
5.3.2 Germany
5.3.2.1 Germany human embryonic stem cells market, 2014 - 2025 (USD Million)
5.3.3 UK
5.3.3.1 UK human embryonic stem cells market, 2014 - 2025 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific human embryonic stem cells market, 2014 - 2025 (USD Million)
5.4.2 Japan
5.4.2.1 Japan human embryonic stem cells market, 2014 - 2025 (USD Million)
5.4.3 China
5.4.3.1 China human embryonic stem cells market, 2014 - 2025 (USD Million)
5.5 Latin America
5.5.1 Latin America human embryonic stem cells market, 2014 - 2025 (USD Million)
5.5.2 Brazil
5.5.2.1 Brazil human embryonic stem cells market, 2014 - 2025 (USD Million)
5.6 Middle East & Africa (MEA)
5.6.1 Middle East & Africa human embryonic stem cells market, 2014 - 2025 (USD Million)
5.6.2 South Africa
5.6.2.1 South Africa human embryonic stem cells market, 2014 - 2025 (USD Million)
Chapter 6 Competitive Landscape
6.1 Strategy Framework
6.2 Market Participation Categorization
6.3 Company Profiles
6.3.1 Astellas Pharma Inc/ Ocata Therapeutics
6.3.1.1 Company overview
6.3.1.2 Financial performance
6.3.1.3 Product benchmarking
6.3.1.4 Strategic initiatives
6.3.2 STEMCELL Technologies Inc.
6.3.2.1 Company overview
6.3.2.2 Financial performance
6.3.2.3 Product benchmarking
6.3.2.4 Strategic initiatives
6.3.3 BIOTIME, INC. / Cell Cure Neurosciences LTD
6.3.3.1 Company overview
6.3.3.2 Financial performance
6.3.3.3 Product benchmarking
6.3.3.4 Strategic initiatives
6.3.4 Thermo Fisher Scientific, Inc.
6.3.4.1 Company overview
6.3.4.2 Financial performance
6.3.4.3 Product benchmarking
6.3.4.4 Strategic initiatives
6.3.5 CellGenix GmbH
6.3.5.1 Company overview
6.3.5.2 Financial performance
6.3.5.3 Product benchmarking
6.3.5.4 Strategic initiatives
6.3.6 ESI BIO
6.3.6.1 Company overview
6.3.6.2 Financial performance
6.3.6.3 Product benchmarking
6.3.6.4 Strategic initiatives
6.3.7 PromoCell GmbH
6.3.7.1 Company overview
6.3.7.2 Financial performance
6.3.7.3 Product benchmarking
6.3.7.4 Strategic initiatives
6.3.8 Lonza
6.3.8.1 Company overview
6.3.8.2 Financial performance
6.3.8.3 Product benchmarking
6.3.9 Kite Pharma
6.3.9.1 Company overview
6.3.9.2 Financial performance
6.3.9.3 Product benchmarking
6.3.9.4 Strategic initiatives
6.3.10 Cynata
6.3.10.1 Company overview
6.3.10.2 Financial performance
6.3.10.3 Product benchmarking
6.3.10.4 Strategic initiatives
6.3.11 Sumanas, Inc.
6.3.11.1 Company overview
6.3.11.2 Financial performance
6.3.11.3 Product benchmarking
6.3.11.4 Strategic initiatives
6.3.12 LifeCell
6.3.12.1 Company overview
6.3.12.2 Financial performance
6.3.12.3 Product benchmarking
6.3.13 International Stem Cell Corporation
6.3.13.1 Company overview
6.3.13.2 Financial performance
6.3.13.3 Product benchmarking
6.3.13.4 Strategic initiatives
6.3.14 Cordlife
6.3.14.1 Company overview
6.3.14.2 Financial performance
6.3.14.3 Product benchmarking
6.3.14.4 Strategic initiatives
6.3.15 Genea BioCells
6.3.15.1 Company overview
6.3.15.2 Financial performance
6.3.15.3 Product benchmarking
6.3.15.4 Strategic initiatives
6.3.16 Geron
6.3.16.1 Company overview
6.3.16.2 Financial performance
6.3.16.3 Product benchmarking
6.3.16.4 Strategic initiatives
List of Tables TABLE 1 North America human embryonic stem cells market estimates& forecasts, by application, 2014 - 2025 (USD Million) TABLE 2 U.S. human embryonic stem cells market estimates& forecasts, by application, 2014 - 2025 (USD Million) TABLE 3 Canada human embryonic stem cells market estimates& forecasts, by application, 2014 - 2025 (USD Million) TABLE 4 Europe human embryonic stem cells market estimates& forecasts, by application, 2014 - 2025 (USD Million) TABLE 5 Germany human embryonic stem cells market estimates& forecasts, by application, 2014 - 2025 (USD Million) TABLE 6 UK human embryonic stem cells market estimates& forecasts, by application, 2014 - 2025 (USD Million) TABLE 7 Asia Pacific human embryonic stem cells market estimates& forecasts, by application, 2014 - 2025 (USD Million) TABLE 8 Japan human embryonic stem cells market estimates& forecasts, by application, 2014 - 2025 (USD Million) TABLE 9 China human embryonic stem cells market estimates& forecasts, by application, 2014 - 2025 (USD Million) TABLE 10 Latin America human embryonic stem cells market estimates& forecasts, by application, 2014 - 2025 (USD Million) TABLE 11 Brazil human embryonic stem cells market estimates& forecasts, by application, 2014 - 2025 (USD Million) TABLE 12 MEA human embryonic stem cells market estimates& forecasts, by application, 2014 - 2025 (USD Million) TABLE 13 South Africa human embryonic stem cells market estimates& forecasts, by application, 2014 - 2025 (USD Million)
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
